La chaîne d'options affiche les données clés des options sur actions de Innate Pharma à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Innate Pharma..

Innate Pharma (NASDAQ:IPHA) Stock, Chaîne d'Options

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) CEO Lip-Bu Tan said Thursday that he met with Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to explore a partnership as the former struggled to ramp up <a target="_blank" href="https://www.benzinga.com/topic/chip-stocks" rel="noreferrer noopener">its foundry business</a>.
Tan hinted at his plans to boost the struggling chipmaker&#8217;s prospects by fostering a return to the office mandate and focusing on core engineering work, Reuters cites from an investor meeting.
The chipmaker plans to reduce operational expenses to $17 billion in 2025 and $16 billion in 2026 while cutting its 2025 capital expenditure target from $20 billion to $18 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44990084/taiwan-semiconductor-to-begin-production-of-14-nm-chips-in-2028-enhancing-ai-and-smartphone-performance" rel="noreferrer noopener">Taiwan Semiconductor To Begin Production Of Advanced 1.4nm Chips In 2028</a>
On Thursday, Intel reported <a target="_blank" href="https://www.benzinga.com/markets/equities/25/04/45001410/intel-ceo-lip-bu-tan-takes-bold-steps-to-revive-chipmaker-says-bureaucracy-is-suffocating-the-innovation" rel="noreferrer noopener">first-quarter revenue</a> of $12.67 billion, surpassing analyst expectations of $12.3 billion. Adjusted earnings of 13 cents per share topped the projected 1 cent. However, Intel forecasts second-quarter revenue between $11.2 billion and $12.4 billion, below the $12.84 billion analysts expected.
Reuters cited CFO David Zinsner during the investor meeting as saying tariff concerns prompted customers to hoard Intel chips, boosting sales in the first quarter. However, the company, unable to determine the tariff concerns induced surplus, expects the second quarter to suffer.
Zinsner said the very fluid trade policies in the U.S. and beyond and regulatory risks have increased the chance of an economic slowdown with the probability of a recession growing.
China imports $10 billion worth of chips from the U.S. annually. About $8 billion of these are central processing units (CPUs) assembled by Intel in the U.S., Reuters cited Bernstein analysts.
Intel stock plunged 38% in the last 12 months as it <a target="_blank" href="https://www.benzinga.com/25/04/44792707/intel-stock-surges-5-on-potential-altera-sale-trumps-tariff-relief-provides-added-boost" rel="noreferrer noopener">failed to capitalize</a> on the shift to artificial intelligence accelerators, similar to those of&nbsp;Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&nbsp;and&nbsp;Taiwan Semiconductor.
Intel fired its chief&nbsp;Pat Gelsinger&nbsp;in 2024 after his turnaround plan to take on Taiwan Semiconductor failed to impress the board.
Intel <a target="_blank" href="https://www.benzinga.com/25/01/42826372/intel-struggles-to-compete-with-amd-and-nvidia-in-data-centers-and-ai-chips" rel="noreferrer noopener">struggled as rivals</a> Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Nvidia captured market share in data centers, AI, and GPUs, impacting profitability.
Intel reportedly tapped Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/media/25/04/44962945/intel-taps-taiwan-semiconductor-for-advanced-2nm-process-for-ai-powered-chips-report" rel="noreferrer noopener">for a 2nm process</a> to manufacture Nova Lake PC chips, which are expected to be available in 2026.
Recently, Taiwan Semiconductor&nbsp;told Bloomberg that&nbsp;it had not&nbsp;discussed forming a venture or sharing its technology with any company, dismissing speculation of a possible collaboration with Intel.
Price Actions:&nbsp;At the last check Friday, INTC stock was down 8.05% to $19.77 premarket.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44978860/stmicro-calls-out-bottom-in-q1-forecasts-q2-rebound-focusing-on-cost-cuts" target="_blank" rel="noreferrer noopener">STMicro Calls Out Bottom In Q1, Forecasts Q2 Rebound Focusing On Cost Cuts</a></li>
</ul>
Photo Courtesy: Tada Images On Shutterstock.com

News

Tech

Media

INTC

NVDA

Intel Weighs Taiwan Semiconductor Partnership To Boost Chip Game

Even after a powerful rebound after the early-April tariff-driven selloff, Bank of America&#8217;s chief investment strategist Michael Harnett says the case for a lasting bull market still depends on a rare trio of conditions that remains out <a href="https://www.benzinga.com/topic/expert-ideas">of reach for now.</a>
In his regular &#8220;The Flow Show&#8221; report, titled &#8220;Stay BIG, sell rips&#8221; and shared Friday, the renowned contrarian strategist said he remains a buyer of dips in bonds, international stocks and gold — forming the acronym BIG — while selling into rallies in U.S. stocks and the dollar.
&#8220;If no recession, equity lows are in, simple; but can&#8217;t jump back on bull&nbsp;unless&nbsp;Treasury yields&nbsp;falling below&nbsp;4%, and&nbsp;earnings growth&nbsp;stays above&nbsp;5%&#8221; Hartnett said.
<h2 class="wp-block-heading">Are Stocks Still Oversold?</h2>
Despite the recent rebound, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) remains 12% below its all-time highs reached in February. 
Market internals tell a grimmer story: Harnett said that 304 stocks in the S&amp;P 500 and 58 in the Nasdaq 100 are still trading below their 2021-22 highs.
This broad-based weakness highlights what Harnett described as a &#8220;remarkable flip from &#8216;U.S. exceptionalism&#8217; hubris to &#8216;U.S. repudiation.'&#8221;
Technically, only one-third of stocks in the S&amp;P 500 and Nasdaq 100 are trading above their 200-day moving averages, suggesting the damage from the April selloff runs deep across sectors.
<h2 class="wp-block-heading">Three Catalysts Needed For A Sustainable Rally</h2>
For a sustained bull market to materialize, Harnett identified three essential conditions: lower Treasury yields driven by Fed cuts, a meaningful reduction in U.S.-China tariffs, and a robust American consumer.
On monetary policy, the strategist pointed to shifting expectations around rate cuts. Market-implied probabilities show just an 8% chance of a cut at the May 7 Federal Open Market Committee meeting, rising to 65% by June 18 and reaching 100% by July 30.
Regarding trade, Harnett said a minimum requirement would be a U.S.-China peace deal that slashes current tariffs—now standing at 145%—to levels well below the 60% range promised during Donald Trump&#8216;s election campaign.
On the consumer side, Harnett cited immigration data showing Southwest border encounters falling to 11,000 per month in February and March from an average of over 100,000 per month in 2024, and a peak of 300,000 in December 2023. This decline could bolster a tight labor market, supporting consumer spending.
Yet headwinds remain strong. U.S. household equity wealth is down $6 trillion year-to-date, Bank of America data show, putting pressure on the top 10% of earners who account for 50% of U.S. consumer spending—the highest concentration since 1989.
Harnett highlighted that the relative performance of Ferrari N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) compared to Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is at its lowest in nine months. This signals a broader trend of investors rotating away from luxury and discretionary sectors toward more necessity-driven, defensive stocks.
Inflation expectations, meanwhile, have surged to levels not seen since 1981, threatening to lift household savings rates and curb spending.
<h2 class="wp-block-heading">A New Era For Stock Valuations?</h2>
Zooming out, Harnett said 2025 could mark a pivotal turning point for stock valuation. After years of ultra-low rates, massive fiscal stimulus, and booming asset prices, a &#8220;new world order&#8221; on valuations may now emerge.
Historically, the average price-to-earnings ratio (P/E) for the S&amp;P 500 was 14x in the 20th century and 20x in the 21st century. In recent years, 20x acted as a floor thanks to globalization, technology advances and the AI boom.
&#8220;In December 2024, $18tn market cap of&nbsp;Magnificent 7&nbsp;was almost on par with&nbsp;$20tn GDP of G7&nbsp;economies&nbsp;ex-USA,&#8221; Hartnett said. 
Going forward, Harnett said 20x could become the ceiling for valuations, citing the reversal of globalization, diminished Fed independence, and a new inflation normal of 3%-4% outside of recessions.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/45003860/us-stock-futures-mixed-after-three-day-winning-streak-expert-dismisses-market-pessimism-says-this-isnt-stuff-you-see-in-bear-market">US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says &#8216;This Isn&#8217;t Stuff You See In Bear Market&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

Analyst Ratings

ETFs

RACE

'Stay BIG, Sell Rips': Hartnett Doubts Bull Market Without 3 Key Catalysts

Piper Sandler analyst Thomas Champion maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Overweight and raises the price target from $185 to $195.

Price Target

GOOGL

Piper Sandler Maintains Overweight on Alphabet, Raises Price Target to $195

Correction: Needham analyst Ryan Koontz initiates coverage on Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy rating and announces Price Target of $28. (Rating change from Reiterate to initiate)

Initiation

RKLB

Correction: Needham Initiates Coverage On Rocket Lab USA with Buy Rating, Announces Price Target of $28 (Rating change from Reiterate to initiate)

WIIM

AVTR

Avantor shares are trading lower following a Q1 revenue miss and a CEO transition.

Centene Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) reported on Friday that its first-quarter&nbsp;2025 sales were&nbsp;$46.62 billion, up 15% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of&nbsp;$43.36 billion</a>.
The insurance firm reported adjusted EPS of $2.90, up 28%, beating the consensus of $2.54.
For the first quarter of 2025, premium and service revenues increased 17% to&nbsp;$42.5 billion&nbsp;from&nbsp;$36.3 billion&nbsp;a year ago, primarily driven by premium and membership growth in the PDP business, strong product positioning, and overall market growth <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45003190/centene-corporation-reports-first-quarter-2025-results" rel="noreferrer noopener">in the Marketplace business</a>.
The health benefits ratio (HBR) of 87.5% for the first quarter of 2025 represents an increase from 87.1% a year ago due to higher Medicaid HBR due to influenza-and-like illnesses.
<ul>
<li>The company adds that the Medicaid HBR in the first quarter of 2024 was not meaningfully impacted by the redetermination-related acuity pressure, which escalated in the second quarter of 2024.</li>
<li>The increase in HBR was partially offset by a decrease in Medicare due to program changes in the Part D business due to the Inflation Reduction Act compared to the first quarter of 2024 and the resulting change in the quarterly progression of the Medicare segment HBR.</li>
<li>Total membership reached 27.94 million, down from 28.42 million a year ago.</li>
<li>Medicaid membership fell from 13.29 million to 12.96 million.</li>
<li>The company saw membership increases of 29% in Marketplace to 5.63 million and 22% in Medicare Prescription Drug Plan (PDP) to 7.87 million compared to the first quarter of 2024.</li>
</ul>
Centene CEO Sarah London noted that the company&#8217;s full-year 2025 adjusted diluted earnings per share outlook was greater than $7.25.
Guidance: Centene raised its 2025 premium and service revenue guidance window by $6 billion on Friday. The company now expects 2025 premium and service revenue of $164 billion to $166 billion compared to $158 billion-$160 billion expected earlier, including:
<ul>
<li>$5 billion of additional Marketplace premium revenue due to outperformance in enrollment throughout the first quarter.</li>
<li>Outperformance in the Medicare Advantage annual enrollment period resulting in&nbsp;$1.0 billion&nbsp;of additional premium revenue.</li>
</ul>
Centene reaffirms fiscal year 2025 <a href="https://www.benzinga.com/25/02/43470058/insurance-firm-centenes-q4-earnings-enrollment-and-premium-boost-revenue-to-offset-lower-medicaid-enrollment-sticks-to-annual-forecast">adjusted EPS of greater than&nbsp;$7.25</a> compared to consensus of $7.23.
Price Action: Centene stock is down 1.19% at $60.85 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44999959/how-the-us-china-trade-war-is-unintentionally-boosting-demand-for-intels-older-chips-amid-economic-uncertainty" target="_blank" rel="noreferrer noopener">Intel&#8217;s Older Parts Are In Demand Thanks To US-China Trade War: &#8216;Tariffs Have Everybody Hedging Their Bets,&#8217; Says Executive</a></li>
</ul>

Earnings

Guidance

Health Care

General

Insurer Centene Reaffirms Annual Profit Guidance, Reports Better Than Expected Q1 Earnings

Citigroup analyst Ygal Arounian maintains Bumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>) with a Neutral and lowers the price target from $6.8 to $4.8.

BMBL

Citigroup Maintains Neutral on Bumble, Lowers Price Target to $4.8

Intensity Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares are trading lower by 30.3% to 62 cents during Friday&#8217;s session after the company announced the pricing of a public offering expected to <a href="https://www.benzinga.com/pressreleases/25/04/n45005681/intensity-therapeutics-inc-announces-2-35-million-public-offering">raise approximately $2.35 million.</a>
What To Know: The offering involves the sale of over 3.1 million shares of common stock and accompanying Series B-1 and B-2 warrants, priced at 75 cents per share and warrant package. Both warrant series are exercisable at 85 cents per share, with the B-1 warrants expiring in five years and B-2 warrants in 18 months. 
The offering, conducted on a &#8220;reasonable best efforts&#8221; basis, is expected to close on or about April 28, pending customary closing conditions. 
Proceeds will support patient enrollment in the Company's INVINCIBLE-4 clinical trial, continued treatment in the INVINCIBLE-3 study and general corporate operations. 
A.G.P./Alliance Global Partners is leading the placement, with Brookline Capital Markets acting as co-placement agent.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/04/45003860/us-stock-futures-mixed-after-three-day-winning-streak-expert-dismisses-market-pessimism-says-this-isnt-stuff-you-see-in-bear-market">US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says &#8216;This Isn&#8217;t Stuff You See In Bear Market&#8217;</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, INTS has a 52-week high of $5.28 and a 52-week low of $0.59.

INTS

Why Intensity Therapeutics (INTS) Stock Is Getting Hammered

Citigroup analyst Ygal Arounian maintains Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) with a Neutral and lowers the price target from $18 to $14.

ANGI

Citigroup Maintains Neutral on Angi, Lowers Price Target to $14

Colgate-Palmolive Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45004176/colgate-announces-1st-quarter-2025-results" rel="noreferrer noopener">trading higher in premarket</a> on Friday after the first-quarter FY25 earnings report.
The company's <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45004176/colgate-announces-1st-quarter-2025-results" rel="noreferrer noopener">first-quarter FY25 sales</a> declined 3% year over year to $4.91 billion, beating the analyst consensus estimate of $4.86 billion.
Organic sales increased by 1.4%. Total Oral, Personal, and Home Care net sales increased&nbsp;by&nbsp;6.8% to $3.96 billion.
Non-GAAP EPS of $0.91 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus </a>estimate of $0.86.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/04/44977669/pepsico-ceo-warns-of-tariffs-led-increase-in-supply-chain-costs-cuts-annual-profit-outlook" rel="noreferrer noopener">PepsiCo CEO Warns Of Tariffs Led ‘Increase In Supply Chain Costs,' Cuts Annual Profit Outlook</a>
Colgate's gross profit was $2.98 billion, while the margin expanded 80 basis points to 60.8%. Selling, general and administrative expenses slipped 0.9% to $1.8 billion.
Operating margin expanded 120 basis points to 21.9%, and operating income increased 2.8% to $1.07 billion for the quarter.
As of March 31, the company had $1.11 billion in cash and equivalents, and its operating cash flow totaled $600 million.
"As we look ahead, uncertainty and volatility in global markets, including the impact of tariffs, remain challenging. We are confident in our strategy and will continue to execute with focus and agility to mitigate these factors and achieve our revised 2025 financial targets," said Chairman, President, and CEO Noel Wallace.
Outlook FY25: Colgate expects net sales to be up in the low single digits, including a negative impact from foreign exchange in the low single digits.
The company anticipates organic sales growth to be 2% to 4%.
The current outlook is better from the last quarter, where <a target="_blank" href="https://www.benzinga.com//node/43385529" rel="noreferrer noopener">it expected FY25 net sales</a> to be roughly flat, including a mid-single-digit negative impact from foreign exchange.
On a non-GAAP basis, the company expects gross profit margin and advertising to be roughly flat as a percentage of net sales and earnings per share to be up in the low single digits.
Price Action: CL shares traded higher by 1.19% at $93.80 in premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44996394/chipotle-battles-slumping-sales-but-honey-chicken-boosts-hope-say-analysts" target="_blank" rel="noreferrer noopener">Chipotle Battles Slumping Sales, Analyst Pin Hope On Honey Chicken</a></li>
</ul>
Photo by EDSON DE SOUZA NASCIMENTO via Shutterstock

Colgate-Palmolive CEO Wallace Says 'Impact Of Tariffs Remain Challenging,' But Raises Annual Revenue Outlook Slightly

Charter Communications Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) reported its <a href="https://www.benzinga.com/pressreleases/25/04/n45004240/charter-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">fiscal first-quarter 2025</a> results Friday, including quarterly revenue growth of 0.4% year-on-year to $13.74 billion, beating the analyst consensus estimate of $13.68 billion.
EPS of $8.42 missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $8.67.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/44930091/t-mobiles-long-game-five-year-price-lock-takes-a-jab-at-verizon" rel="noreferrer noopener">T-Mobile&#8217;s Long Game: Five-Year Price Lock Takes A Jab At Verizon</a>
The topline performance reflects revenue growth of 33.5% for residential mobile service, 1.8% for residential Internet and 13.4% for other revenue.
Charter lost 60,000 internet customers, including approximately 9,000 customer disconnects related to the wildfires in California in January, compared to a decline of 72,000 during the first quarter of 2024.
Comcast Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) lost 199,000 <a href="https://www.benzinga.com/news/earnings/25/04/44978343/comcast-hit-hard-by-subscriber-exodus-nearly-630000-customers-gone-in-q1" target="_blank" rel="noopener">broadband customers </a>amid competition with telecom companies. AT&amp;T Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) Consumer Wireline segment had 261 AT&amp;T Fiber net additions during the quarter. Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) had 339,000 broadband net additions during the quarter.
Charter&#8217;s residential video customers decreased by 181,000 compared to 405,000 in the previous year. Comcast also lost 427,500 video subscribers as streaming giants like Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) gained traction.
Charter&#8217;s total mobile lines increased by 514,000 during the quarter, reaching 10.4 million as of March 31, 2025. AT&amp;T&#8217;s 324,000 postpaid phone net adds (versus 349,000 a year ago). Contrastingly, Verizon&#8217;s quarterly postpaid phone net losses were 289,000 versus 114,000 net losses Y/Y driven by price hikes, intense rival promotional offers, and lower government support.
Adjusted EBITDA margin expanded by 180 bps to 42.0%.
The quarterly free cash flow of $1.56 billion increased from $358 million in the prior year, driven by higher net cash flows from operating activities and lower capital expenditures.
As of March 31, Charter served 30.02 million residential and SMB Internet customers.
Net cash flow from operating activities totaled $4.24 billion during the quarter. As of March 31, the company held $796 million in cash and equivalents.
2025 Outlook:&nbsp;Charter Communications&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/43390140/charter-q4-earnings-beats-estimates-mobile-growth-surges-with-529k-new-lines-despite-broadband-subscriber-losses" rel="noreferrer noopener">reiterated a capex</a> of $12 billion (versus $11.27 billion <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">in fiscal 2024</a>).
CHTR Price Action: Charter Communications stock is up 1.99% to $342.00 in the premarket at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44993820/imax-gains-analyst-praise-for-strong-q1-china-growth-but-tariff-film-import-risks-loom" target="_blank" rel="noreferrer noopener">Imax Wins Analyst Praise On Strong Film Slate, But China Market Volatility Raises Concerns</a></li>
</ul>
Photo: Shutterstock

CHTR

CMCSA

NFLX

Charter Loses Internet And TV Subscribers But Beats Rivals With Strong Mobile Line Gains

HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=i9M1ev8j-ugWH7tghn200BffaLeFxwfXOhwKgRWPaOCFJYC_Xo6TqF-skp8x-7VJI-svlz_pQIM1Q5g0vQvODq97M4XUnIxX22RuLEaQoIs=">Freight Technologies, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>, "Fr8Tech" or the "Company"))), a logistics management innovation company, is pleased to announce its integration with supply chain management company <a href="https://www.globenewswire.com/Tracker?data=xrDzz1f-4wVhq7yOAwjPyVOn1-lXn1_YHPUbvmYy2sKUv3W7atuejuVhAvQCAh5X16d-j9EkuixAwN4xsIvmcQ==">Blue Yonder</a>'s Transportation Management System ("TMS") through Bayer Crop Science LP ("Bayer"). This follows Bayer's selection of Fr8Tech as a key logistics provider in September 2024 for the 2025 season, where Fr8Tech was awarded six critical cross-border lanes for truckload services.
 &nbsp;

FRGT

Freight Technologies Integrates With Blue Yonder's Transportation Management System Through Bayer Crop Science To Optimize Supply Chain Efficiency

Skechers USA Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares are trading lower by 5.7% to $47.61 during Friday&#8217;s session. The company late Thursday announced record first-quarter 2025 sales of $2.41 billion, up 7.1% year-over-year, though <a href="https://www.benzinga.com/news/earnings/25/04/44996051/skechers-stock-falls-on-q1-revenue-miss-details">slightly below analyst expectations</a> of $2.43 billion. 
What To Know: EPS came in at $1.34, beating the consensus estimate of $1.17. International sales represented 65% of the total, with notable regional gains in Europe, Middle East and Africa (up 14%) and the Americas (up 8%), while Asia-Pacific declined 3% due to softness in China. On a constant currency basis, total sales rose 9%.
Both wholesale and direct-to-consumer segments grew, up 7.8% and 6% respectively. Gross margin dipped slightly to 52% due to lower average selling prices. 
Skechers emphasized ongoing investment in China and <a href="https://www.benzinga.com/pressreleases/25/04/b44994833/skechers-announces-first-quarter-2025-financial-results-and-record-quarterly-sales">highlighted new innovations</a> like its Hands Free Slip-ins technology and global marketing campaigns.
Despite the strong quarter, Barclays lowered its price target on the stock from $77 to $53, while Piper Sandler cut its target to $45 from $50.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/04/45003860/us-stock-futures-mixed-after-three-day-winning-streak-expert-dismisses-market-pessimism-says-this-isnt-stuff-you-see-in-bear-market">US Stock Futures Mixed After Three-Day Winning Streak: Expert Dismisses Market Pessimism, Says &#8216;This Isn&#8217;t Stuff You See In Bear Market&#8217;</a>
<h2 class="wp-block-heading">How To Buy SKX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Skechers&#8217; case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SKX has a 52-week high of $78.85 and a 52-week low of $44.50.

Skechers Beats Q1 EPS Forecast, Misses Revenue Target: What's Going On?

Barrington Research analyst Michael Petusky maintains Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) with a Outperform and lowers the price target from $111 to $103.

MMSI

Barrington Research Maintains Outperform on Merit Medical Systems, Lowers Price Target to $103

Needham analyst Ryan Koontz reiterates Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy and maintains $28 price target.

Reiteration

Needham Reiterates Buy on Rocket Lab USA, Maintains $28 Price Target

TRNO

Terreno Realty Acquires Industrial Property In Long Island City Queens, New York For About $7.6M

Needham analyst Ryan MacDonald reiterates Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Buy and maintains $11 price target.

COUR

Needham Reiterates Buy on Coursera, Maintains $11 Price Target

LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>) stock traded lower premarket on Friday after the company reported mixed <a href="https://www.benzinga.com/pressreleases/25/04/g45003699/lyondellbasell-reports-first-quarter-2025-earnings" target="_blank" rel="noreferrer noopener">first-quarter 2025 results</a>.
LyondellBasell posted revenue of $7.677 billion, down 7.6% year-over-year but topping estimates of $7.47 billion. Adjusted EPS came in at 33 cents, missing the consensus of 43 cents.
Adjusted EBITDA stood at 576 million (-40.2% YoY), and the margin contracted 410 bps to 7.5%.
U.S. polyethylene margins fell due to maintenance and higher feedstock costs, while polypropylene volumes rose 12% with better utilization.
European polyethylene profitability improved with increased cracker utilization and seasonal demand; rising natural gas prices hit acetyls and oxyfuels margins.
LyondellBasell used $579 million in operating cash flow in Q1, driven by higher receivables, inventory buildup, and delayed tax payments. The company invested $483 million in capex and returned $543M to shareholders via dividends and buybacks, maintaining a balanced strategy.
LyondellBasell ended the quarter with $1.9 billion in cash and $6.5 billion in total available liquidity, exceeding its 12-month cash conversion target.
LyondellBasell advanced its three-pillar strategy by approving a U.S. propylene expansion, securing cost-advantaged feedstocks in Saudi Arabia, exiting non-core Dutch and refinery assets, and launching a $500M 2025 Cash Improvement Plan.
Peter Vanacker, LyondellBasell&#8217;s chief executive officer, said the company continues to &#8220;take sensible measures&#8221; to strengthen its near-term cash generation amid a prolonged industry downturn. 
&#8220;Our financial and operational discipline enables us to effectively navigate macroeconomic challenges, achieve sustainable growth and provide a strong and reliable dividend throughout the cycle," added Vanacker.
Q2 Outlook: The company expects seasonal demand recovery, easing U.S. feedstock costs, and improved oxyfuels margins amid summer gasoline demand.
LyondellBasell projects Q2 asset operating rates of 85% for North American O&amp;P, 75% for European O&amp;P, and 85% for I&amp;D segments.
Price Action: LYB shares traded lower by 1.34% at $58.40 premarket at the last check Friday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/04/45003278/flexport-ceo-joins-galloway-tariff-workarounds-and-fraud-will-force-trump-to-walk-back-on-trade-war-with-china" target="_blank" rel="noreferrer noopener">Trump Will Be First To ‘Blink' In China Trade War, Flexport's Ryan Petersen Tells Scott Galloway</a></li>
</ul>

LyondellBasell Misses Q1 Estimates, Stock Slips As Profit Margins Narrow

BEIJING, April 25, 2025 /PRNewswire/ -- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>), a one-stop AI video solution provider, announced a Letter to Investors, in which Baijiayun CEO Mr. Yi Ma stated that following its partnership with Xinlantian, the company plans to invest tens of millions of dollars over the next five years to establish new ecosystem for autism rehabilitation.
 &nbsp;

Baijiayun Group Plans To Invest Tens Of Millions Of Dollars Over Next Five Years To Establish New Ecosystem For Autism Rehabilitation

Deutsche Bank has revised its forecast for the S&amp;P 500, attributing the change to potential harm to corporate earnings caused by tariff policies.
What Happened: Deutsche Bank has lowered its year-end expectation for the S&amp;P 500 to 6,150, a significant reduction from its earlier target of 7,000. The bank&#8217;s analysis suggests that tariff hikes will disproportionately affect American companies, equating to an &#8220;$800 billion tax increase,&#8221; <a href="https://www.businessinsider.com/stock-market-outlook-tariffs-impact-tax-increase-trade-war-2025-4">reported </a>Business Insider.
The bank calculated this figure by applying the new effective U.S. tariff rate of around 25% to $3.25 trillion worth of goods imported to the U.S. last year. A team led by chief strategist Binky Chadha noted, &#8220;U.S. corporates intermediate most goods imports, whether for consumption or as components for further processing, and we see them bearing the bulk of the tariff hit with few avenues for relief.
Chadha indicated that a decline in presidential approval ratings might be the trigger for reversing tariff policy, though that shift hasn't occurred yet. A sustained market rally could follow a credible positive move on trade, potentially emerging if President Donald Trump's approval falls into the low-40s or 30s.
As a result, Deutsche Bank now projects S&amp;P 500 earnings-per-share to hit &#8220;$240&#8221; this year, a 15% decrease from its previous forecast and a 5% decline from 2024 earnings. The bank also expects the S&amp;P 500 to trade between 4,600 and 5,600, with positive news on tariffs potentially triggering a sharp upside.
SEE ALSO:&nbsp;<a href="https://benzinga.com/25/04/45002083/court-documents-reveal-charges-filed-against-dc-tesla-vandalism-suspect-report" target="_blank" rel="noreferrer noopener">DC Man Arrested For Vandalizing Tesla Cars In &#8216;Tesla Takedown&#8217; Protest, Faces June Court Date</a>
Why It Matters: This revision comes amid concerns over the impact of tariffs on the market. On Thursday,&nbsp;<a href="https://www.benzinga.com/markets/equities/25/04/45004528/sp-500-could-crash-37-to-3700-if-tariff-fallout-triggers-recession-warns-wolfe-research">Wolfe Research warned</a>&nbsp;that the S&amp;P 500 could plunge to 3,700 points in a mild recession scenario, a potential 37% decline from its January levels, due to tariff-related uncertainties.
Despite these concerns, the market showed signs of resilience. On the same day, the S&amp;P 500 saw a&nbsp;<a href="https://www.benzinga.com/25/04/45001892/sp-500-jumps-2-amid-surge-in-nvidia-tesla-shares-investor-fear-eases-but-fear-greed-index-remains-in-fear-zone">2% rally</a>&nbsp;driven by gains in Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares. However, the market mood remained cautious, reflected in the CNN Money Fear and Greed index still in the &#8220;Fear&#8221; zone.
Deutsche Bank&#8217;s revised forecast underscores the potential impact of tariffs on the market, highlighting the need for investors to closely monitor policy developments.
Year to date, the S&amp;P 500 is 6.5% down and is almost 11% below its February all-time high.&nbsp;
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45002884/bill-gates-ex-wife-melinda-french-gates-brushes-off-criticism-from-elon-musk-and-bill-ackman-says-im-in-the-arena-doing-the-work-on-her-philanthropic-efforts" target="_blank" rel="noreferrer noopener">Bill Gates&#8217; Ex-Wife Melinda French Gates Brushes Off Criticism From Elon Musk And Bill Ackman, Says &#8216;I&#8217;m In The Arena Doing The Work&#8217; On Her Philanthropic Efforts &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments

Innate Pharma

Innate Pharma (IPHA) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL